David Gershenson is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 832 publications with 44,753 citations (h-index 111); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 13 Apr 2011.
Clinical trials
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
- Aadi Bioscience, Inc.Program year20222 payments
- Genentech, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2005–2014 per NIH RePORTER. The latest:
- P3 - Personalized Therapy for Low-Grade Serous Carcinoma of the Ovary
University of Tx Md Anderson Can Ctr
FY2014$183,652P50CA083639
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network
2022 - Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2021 - MEK inhibitor resistance mechanisms and recent developments in combination trials
Cancer Treatment Reviews
2020 - NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Journal of the National Comprehensive Cancer Network
2019 - Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
Journal of Clinical Oncology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”